Immunoassay Market to Reach USD 47.5B by 2031 with 6% CAGR Growth

SHERIDAN, Wyo., Sept. 21, 2026 /CourierPR/ -- The global immunoassay market is projected to grow from USD 35.5 billion in 2026 to USD 47.5 billion by 2031, registering a CAGR of 6% during the forecast period (2026-2031), according to a new study by Wissen Research. This growth is driven by rising prevalence of infectious diseases, cancer, and chronic and autoimmune disorders, alongside growing demand for fast, sensitive, and reliable detection of biomarkers, antibodies, and hormones.

Wider adoption of automated, high-throughput analyzers and continued advances in chemiluminescence, electrochemiluminescence, and multiplex immunoassay technologies are improving diagnostic accuracy while extending testing into decentralized and point-of-care settings.

Where Immunoassay Testing Is Heading: Multiplexing and Digital Detection The next phase of growth in immunoassay testing is being shaped by a shift from single-analyte testing toward multiplex and digital immunoassay platforms capable of detecting several biomarkers simultaneously from a single, minimal-volume sample. Recent advances include barcoded multiplex digital ELISA systems capable of detecting up to eight targets from less than 9 microliters of blood with sensitivity reaching the low-attomolar range, a level of precision that opens the door to broader use in oncology biomarker panels, immune profiling, and precision diagnostics.

At the same time, automation continues to reshape laboratory throughput. High-throughput analyzers such as Roche's cobas e 801 can process more than 300 immunochemistry tests per hour with automated reagent handling and quality control, while integrated platforms like Siemens Healthineers' Atellica Solution combine clinical chemistry and immunoassay testing on a single system. Alongside this, microfluidic and point-of-care immunoassay platforms are extending testing beyond centralized laboratories into hospitals, physician offices, and decentralized clinical settings, supported by continued advances in miniaturization and digital detection.

What's Fueling Growth in the Immunoassay Market - Rising Disease Burden: Growing prevalence of infectious diseases, cancer, cardiovascular disease, and autoimmune disorders is driving demand for accurate, sensitive immunoassay-based testing. - Laboratory Automation: Growing adoption of automated, high-throughput immunoassay analyzers is improving efficiency, reducing manual intervention, and accelerating diagnostic turnaround times. - Expanding Biomarker Applications: Rising demand for early disease detection is broadening immunoassay use across oncology, cardiac testing, endocrine disorders, and infectious disease diagnostics. - Detection Technology Advances: Progress in chemiluminescence, electrochemiluminescence, and fluorescence-based platforms is improving assay sensitivity and specificity. - Point-of-Care Expansion: Growing demand for decentralized testing is driving adoption of rapid immunoassay platforms that support timely diagnosis outside centralized laboratories. - Pharmaceutical and Biotech Research Demand: Increasing use of immunoassays in drug development, therapeutic drug monitoring, and clinical trials is supporting sustained market demand.

Challenges Facing the Immunoassay Market Cost remains a persistent barrier to broader adoption. Advanced automated analyzers and ultrasensitive digital immunoassay platforms require substantial upfront investment, while ongoing reagent, consumable, calibration, and maintenance costs add to the total cost of testing, a burden that can be especially difficult for smaller laboratories and resource-constrained healthcare facilities to absorb.

Analytical consistency presents further challenges. Cross-reactivity, non-specific binding, matrix effects, and interference from heterophile antibodies can all affect result accuracy, and highly sensitive assays require careful control of background signal to avoid false positives. Variation in assay formats, reagents, and calibration standards across different manufacturers and platforms also makes it difficult to achieve consistent results across laboratories, a standardization gap that continues to limit interoperability across the industry.

Recent Strategic Developments in the Immunoassay Market In March 2026, QuidelOrtho partnered with Lifotronic to expand its global immunoassay offering beyond its existing VITROS diagnostic system portfolio. In February 2026, LubioScience and Mabtech entered into a strategic partnership to strengthen availability of ELISA, EYRAplex, ELISpot, and FluoroSpot immunoassay technologies for research and diagnostics customers in Switzerland. In March 2025, Gentian Diagnostics launched the GCAL Calprotectin Immunoassay together with Beckman Coulter Diagnostics, expanding availability of the assay across Beckman Coulter's clinical chemistry platforms.

These moves reflect a market where established diagnostics companies continue to broaden assay menus and international distribution through partnerships, while smaller specialized players expand access to niche and research-focused immunoassay technologies.

Key Insights from Immunoassay Market Analysis - ELISA (enzyme-linked immunosorbent assay) is expected to hold the largest share by technology in 2025, supported by its wide use across clinical laboratories, research institutions, and blood banks, along with broad availability of commercial kits and established laboratory infrastructure. - Hospitals are expected to represent the largest end-user segment in 2025, driven by high diagnostic testing volumes and integrated laboratory platforms combining clinical chemistry and immunoassay testing. - North America held the largest regional share in 2025, supported by advanced healthcare infrastructure and a strong installed base of automated immunoassay analyzers. - Asia-Pacific is projected to register the highest CAGR during 2026-2030, driven by expanding healthcare infrastructure, rising diagnostic testing volumes, and growing adoption of laboratory automation across China and India.